Recently, the anticoagulant drug Xarelto (rivaroxaban) (Bayer Pharmaceuticals, Inc.) has been linked to an increased risk for major bleeding events, prompting a number of Xarelto lawsuits.  In August 2014, medical researcher Eugene Yang published a piece in Vascular Health and Risk Management titled “A clinician’s perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation – full speed ahead or proceed with caution?”, exploring the safety of several anticoagulant drugs.  Here, we will discuss that research.

Yang states, “The aim of this review is to examine this indication from a clinician’s perspective, highlighting efficacy and safety results from the major trials with these novel oral agents. Clinical issues regarding bleeding, monitoring, and reversal are discussed, along with requirements to consider when interrupting treatment with a novel oral anticoagulant for the purpose of transitioning to another anticoagulant and prior to cardioversion, ablation, percutaneous coronary intervention, or emergency surgery.”

First, Yang found that patients using Xarelto only spend an average of 55% of time within the proper therapeutic window, the lowest of all anticoagulants reviewed.  Many doctors believe that if a patient spends less than 60% of the time in that therapeutic window, more harm than good is done.  It is vital to stay in that window, for too little drug places a patient at risk for stroke, and too much places a patient at risk for internal bleeding, which can be fatal.

Studying elderly patients using Xarelto, Yang made some interesting conclusions.  He writes, “Rivaroxaban was noninferior to warfarin (P<0.001) for reduction in the risk of stroke or systemic embolism in the intent-to-treat population; however, superiority was not shown. … The risk of intracranial hemorrhage was significantly lower with rivaroxaban, but the risk of gastrointestinal bleeding was significantly higher”. (emphasis added)

Due to the fact that Bayer has failed time and again to adequately warn users of this risk and does not advocate regular blood tests, Xarelto lawsuits are currently being filed in great number.  If you or a loved one used Xarelto and suffered a major bleeding event, you may be entitled to significant financial compensation.  For a free, no-obligation case consultation, contact our team of Xarelto lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.  Call today and see how we can help.

(855) 452 – 5529

Our Xarelto Lawsuit Information page is a great place to start if you have any questions about Xarelto.